24.99
24.99 (0%)
As of Apr 25, 2025
Viking Therapeutics, Inc. [VKTX]
Source:
Company Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 704-4660 |
| Industry | manufacturing |
| CEO | Brian Lian, Ph. D. |
| Website | www.vikingtherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-55.5 |
| Net Income | $-45.6 |
| Net Cash | $11.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -5.1% |
| Profit as % of Stockholder Equity | -5.4% |
Management Effectiveness
| Return on Equity | -5.4% |
| Return on Assets | -5.3% |
| Turnover Ratio | |
| EBITA | $-55.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $867 |
| Total Liabilities | $20.1 |
| Operating Cash Flow | $-52.3 |
| Investing Cash Flow | $63.2 |
| Financing Cash Flow | $0.3 |
